On Deck For Alnylam: Three Phase III Starts In 2025

The RNAi specialist outlined plans to initiate three Phase III trials this year – two for nucresiran in ATTR amyloidosis and one for zilebesiran for hypertension – during an R&D day in New York.

Key Takeaways

Alnylam showcased its RNAi pipeline during a four-hour R&D day in New York.

A big focus was the next-generation TTR silencer nucresiran and the hepatic angiotensinogen synthesis inhibitor zilebesiran for hypertension, both of which are moving into Phase III.

Further out, management highlighted Phase I assets in neuroscience, including mivelsiran for Alzheimer’s disease and ALN-HTT02 for Huntington’s disease.

The big milestone for Alnylam this year is the expected US Food and Drug Administration approval of Amvuttra (vutrisiran) for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Quick Listen: Scrip’s Five Must-Know Things

09 Jun 2025

• By Ian Haydock

In this week's episode: Sanofi’s Blueprint buy; AstraZeneca’s breast cancer resistance results at ASCO; BMS and BioNTech’s big bispecific deal; Kymera’s Dupixent in a pill; and Degron’s CEO on pipeline and strategy.